BioStock: Saniona aiming for new clinical data and first market approval

In its recently published interim report, Saniona’s CEO Thomas Feldthus highlights the external interest in one of the clinical candidates and two of the preclinical candidates, while reiterating the target of delivering clinical updates for SAN711 and SAN2355 before year-end. The company is also eyeing a possible first market approval of tesofensine, targeting the obesity market.
– We are awaiting the final decision for approval of tesofensine for obesity in Mexico. If successful, Saniona will be entitled to an upfront payment and double-digit royalties on product sales.

Read the article at biostock.se:

https://www.biostock.se/en/2024/09/saniona-aiming-for-new-clinical-data-and-first-market-approval/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/